Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplant: Viral detection in the lung predicts outcome

Clinical Infectious Diseases

Volumn 58, Issue 10, 2014, Pages 1357-1368

  Seo, Sachiko ^a   Xie, Hu ^a   Campbell, Angela P ^a,b,c,e   Kuypers, Jane M ^a,d   Leisenring, Wendy M ^a   Englund, Janet A ^b,c   Boeckh, Michael ^a,d  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Classification.; Hematopoietic cell transplant; Lower respiratory tract disease; Parainfluenza virus

Indexed keywords

IMMUNOGLOBULIN; RIBAVIRIN; STEROID; ANTIVIRUS AGENT;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; COUGHING; CRACKLE; DRUG MEGADOSE; DYSPNEA; FEMALE; FLUOROIMMUNOASSAY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOCOMPROMISED PATIENT; LEUKOCYTE COUNT; LOWER RESPIRATORY TRACT INFECTION; LUNG BIOPSY; LUNG LAVAGE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MYELOABLATIVE CONDITIONING; NEUTROPHIL COUNT; NONHUMAN; OVERALL SURVIVAL; OXYGEN CONSUMPTION; PARAINFLUENZA VIRUS; PARAINFLUENZA VIRUS INFECTION; PRIORITY JOURNAL; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPUTUM ANALYSIS; STEROID THERAPY; TACHYPNEA; UPPER RESPIRATORY TRACT INFECTION; VIRUS DETECTION; VIRUS LOAD; WHEEZING; BRONCHOALVEOLAR LAVAGE FLUID; CLASSIFICATION; ISOLATION AND PURIFICATION; LUNG; MIDDLE AGED; MORTALITY; PARAMYXOVIRIDAE INFECTIONS; PARAMYXOVIRINAE; RESPIRATORY INSUFFICIENCY; RESPIRATORY TRACT INFECTIONS; RISK FACTOR; SURVIVAL RATE; VIROLOGY; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LUNG; MALE; MIDDLE AGED; PARAMYXOVIRIDAE INFECTIONS; PARAMYXOVIRINAE; RESPIRATORY INSUFFICIENCY; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; STEROIDS; SURVIVAL RATE; VIRAL LOAD; YOUNG ADULT;

EID: 84899851797     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu134     Document Type: Article

References (40)

1. Renaud C, Campbell AP. Changing epidemiology of respiratory viral infectionsin hematopoietic cell transplant recipients and solid organtransplant recipients. Curr Opin Infect Dis 2011; 24:333-43.
2. Shah DP, Ghantoji SS, Mulanovich VE, Ariza-Heredia EJ, Chemaly RF.Management of respiratory viral infections in hematopoietic cell transplantrecipients. Am J Blood Res 2012; 2:203-18.
3. Elizaga J, Olavarria E, Apperley J, Goldman J, Ward K. Parainfluenzavirus 3 infection after stem cell transplant: relevance to outcome ofrapid diagnosis and ribavirin treatment. Clin Infect Dis 2001; 32:413-8.
4. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. Parainfluenzavirus infections after hematopoietic stem cell transplantation: risk factors,response to antiviral therapy, and effect on transplant outcome.Blood 2001; 98:573-8.
5. Chemaly RF, Hanmod SS, Rathod DB, et al. The characteristics and outcomesof parainfluenza virus infections in 200 patients with leukemia orrecipients of hematopoietic stem cell transplantation. Blood 2012;119:2738-45; quiz 969.
6. Ustun C, Slaby J, Shanley RM, et al. Human parainfluenza virus infectionafter hematopoietic stem cell transplantation: risk factors, management,mortality, and changes over time. Biol Blood Marrow Transplant2012; 18:1580-8.
7. El Saleeby CM, Somes GW, DeVincenzo JP, Gaur AH. Risk factors forsevere respiratory syncytial virus disease in children with cancer: the importanceof lymphopenia and young age. Pediatrics 2008; 121:235-43.
8. Ljungman P, de la Camara R, Perez-Bercoff L, et al. Outcome of pandemicH1N1 infections in hematopoietic stem cell transplant recipients.Haematologica 2011; 96:1231-5.
9. Milano F, Campbell AP, Guthrie KA, et al. Human rhinovirus andcoronavirus detection among allogeneic hematopoietic stem celltransplantation recipients. Blood 2010; 115:2088-94.
10. Cortez KJ, Erdman DD, Peret TC, et al. Outbreak of human parainfluenzavirus 3 infections in a hematopoietic stem cell transplant population.J Infect Dis 2001; 184:1093-7.
11. Hodson A, Kasliwal M, Streetly M, MacMahon E, Raj K.A parainfluenza-3 outbreak in a SCT unit: sepsis with multi-organ failureand multiple co-pathogens are associated with increased mortality.Bone Marrow Transplant 2011; 46:1545-50.
12. Srinivasan A, Wang C, Yang J, Shenep JL, Leung WH, Hayden RT.Symptomatic parainfluenza virus infections in children undergoinghematopoietic stem cell transplantation. Biol Blood Marrow Transplant2011; 17:1520-7.
13. Kuypers J, Campbell AP, Cent A, Corey L, Boeckh M. Comparisonof conventional and molecular detection of respiratory viruses inhematopoietic cell transplant recipients. Transpl Infect Dis 2009;11:298-303.
14. Seo S, Campbell AP, Xie H, et al. Outcome of respiratory syncytial viruslower respiratory tract disease in hematopoietic cell transplant recipientsreceiving aerosolized ribavirin: significance of stem cell source and oxygenrequirement. Biol Blood Marrow Transplant 2013; 19:589-96.
15. Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P.Fourth European Conference on Infections in Leukaemia (ECIL-4):guidelines for diagnosis and treatment of human respiratory syncytialvirus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus.Clin Infect Dis 2013; 56:258-66.
16. Ljungman P, Ward KN, Crooks BN, et al. Respiratory virus infectionsafter stem cell transplantation: a prospective study from the InfectiousDiseases Working Party of the European Group for Blood and MarrowTransplantation. Bone Marrow Transplant 2001; 28:479-84.
17. Mohty B, Thomas Y, Vukicevic M, et al. Clinical features and outcomeof 2009-influenza A (H1N1) after allogeneic hematopoietic SCT. BoneMarrow Transplant 2012; 47:236-42.
18. Machado CM, Boas LS, Mendes AV, et al. Use of oseltamivir to controlinfluenza complications after bone marrow transplantation. Bone MarrowTransplant 2004; 34:111-4.
19. Small TN, Casson A, Malak SF, et al. Respiratory syncytial virus infectionfollowing hematopoietic stem cell transplantation. Bone MarrowTransplant 2002; 29:321-7.
20. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasivefungal infections in immunocompromised patients with cancer and hematopoieticstem cell transplants: an international consensus. Clin InfectDis 2002; 34:7-14.
21. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasivefungal disease from the European Organization for Research and Treatmentof Cancer/Invasive Fungal Infections Cooperative Group and the NationalInstitute of Allergy and Infectious Diseases Mycoses Study Group(EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-21.
22. Bergeron A, Porcher R, Sulahian A, et al. The strategy for the diagnosisof invasive pulmonary aspergillosis should depend on both the underlyingcondition and the leukocyte count of patients with hematologicmalignancies. Blood 2012; 119:1831-7; quiz 956.
23. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infectionsamong organ transplant recipients: results of the Transplant-AssociatedInfection Surveillance Network (TRANSNET). Clin Infect Dis 2010;50:1101-11.
24. Chen YB, Driscoll JP, McAfee SL, et al. Treatment of parainfluenza 3infection with DAS181 in a patient after allogeneic stem cell transplantation.Clin Infect Dis 2011; 53:e77-80.
25. Drozd DR, Limaye AP, Moss RB, et al. DAS181 treatment of severeparainfluenza type 3 pneumonia in a lung transplant recipient. TransplInfect Dis 2013; 15:E28-32.
26. Shah DP, Ghantoji SS, Shah JN, et al. Impact of aerosolized ribavirin onmortality in 280 allogeneic haematopoietic stem cell transplant recipientswith respiratory syncytial virus infections. J AntimicrobChemother 2013; 68:1872-80.
27. Kumagai Y, Takeuchi O, Akira S. Pathogen recognition by innatereceptors. J Infect Chemother 2008; 14:86-92.
28. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev2009; 227:75-86.
29. Cros J, Cagnard N, Woollard K, et al. Human CD14dim monocytespatrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors.Immunity 2010; 33:375-86.
30. Barbalat R, Lau L, Locksley RM, Barton GM. Toll-like receptor 2 oninflammatory monocytes induces type I interferon in response toviral but not bacterial ligands. Nat Immunol 2009; 10:1200-7.
31. Tang L, Li Q, Bai J, Zhang H, Lu Y, Ma S. Severe pneumonia mortalityin elderly patients is associated with downregulation of Toll-like receptors2 and 4 on monocytes. Am J Med Sci 2014; 347:34-41.
32. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in theactivation and regulation of innate and adaptive immunity. Nat Rev Immunol2011; 11:519-31.
33. Janardhan KS, Sandhu SK, Singh B. Neutrophil depletion inhibits earlyand late monocyte/macrophage increase in lung inflammation. FrontBiosci 2006; 11:1569-76.
34. Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C.IL-6: a regulator of the transition from neutrophil to monocyte recruitmentduring inflammation. Trends Immunol 2003; 24:25-9.
35. Lewis VA, Champlin R, Englund J, et al. Respiratory disease due to parainfluenzavirus in adult bone marrow transplant recipients. Clin InfectDis 1996; 23:1033-7.
36. Chakrabarti S, Collingham KE, Holder K, Oyaide S, Pillay D, MilliganDW. Parainfluenza virus type 3 infections in hematopoetic stem celltransplant recipients: response to ribavirin therapy. Clin Infect Dis2000; 31:1516-8.
37. Dignan F, Alvares C, Riley U, et al. Parainfluenza type 3 infection poststem cell transplant: high prevalence but low mortality. J Hosp Infect2006; 63:452-8.
38. Chakrabarti S, Collingham KE, Holder K, Fegan CD, Osman H, MilliganDW. Pre-emptive oral ribavirin therapy of paramyxovirus infectionsafter haematopoietic stem cell transplantation: a pilot study.Bone Marrow Transplant 2001; 28:759-63.
39. Sparrelid E, Ljungman P, Ekelof-Andstrom E, et al. Ribavirin therapy inbone marrow transplant recipients with viral respiratory tract infections.Bone Marrow Transplant 1997; 19:905-8.
40. Falsey AR. Current management of parainfluenza pneumonitis inimmunocompromised patients: a review. Infect Drug Resist 2012;5:121-7.